Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

MariMed Inc. Reports $44.23 Million in Q3 2026 Revenue as Net Loss Widens to $3.50 Million

MariMed Inc. achieved a 9% increase in year-over-year revenue during the third quarter of 2026, reaching $44.23 million. However, the company faced a widening net loss of $3.50 million as high interest expenses and income tax provisions weighed on its bottom-line performance.

Colorado marijuana grow, marijuana dispensary, growing marijuana, growing cannabis. Stock photo illustrating MariMed's financial results story.
MARIMED INC. · Photo: noexcusesradio / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 44.2340.76
Gross Profit 17.1616.36
Pretax Income -0.74-0.18
Net Income -3.50-2.95
Diluted EPS -0.01-0.01
Net Income YoY
-18.9%

Key highlights

  • Revenue grew 9% year-over-year to $44.23 million compared to $40.76 million in Q3 2025
  • Gross profit improved to $17.16 million, up from $16.36 million in the prior year period
  • Net loss widened by 18.9% to $3.50 million, largely driven by tax and interest costs
  • Pretax loss increased to $0.74 million from a $0.18 million loss in the year-ago quarter
  • Cash and cash equivalents stood at $10.4 million as of November 2026

How the Period Went

Revenue reached $44.23 million for the quarter ended September 30, 2026, marking a 9% improvement over the $40.76 million recorded in the same period the previous year. Despite this steady top-line growth, the bottom line saw a widening deficit during the period. The company reported a net loss of $3.50 million, representing an 18.9% increase in losses compared to the $2.95 million net loss reported in the third quarter of 2025. Diluted earnings per share remained steady at a loss of $0.01. These results highlight a period where rising operational scale was hindered by non-operating financial headwinds.

Margins and Profitability

Gross profit for the third quarter rose to $17.16 million, up from $16.36 million in the prior year, reflecting the company's ability to maintain core margins amid expansion. However, overall profitability was significantly hindered by substantial income tax provisions and ongoing interest expenses, which pushed pretax income to a loss of $0.74 million. This compares to a narrower pretax loss of $0.18 million in the year-ago quarter. The company’s ability to convert increased sales into net earnings continues to be impacted by a high-interest rate environment and the unique federal tax burdens that currently affect most operators in the domestic cannabis industry.

Business Overview

MariMed Inc. operates as a multi-state cannabis company dedicated to improving lives through high-quality products and services. The company manages a diverse portfolio of brands across cultivation, production, and retail dispensaries. Its operations are concentrated in key US markets, where it serves both medicinal and adult-use customers with a focus on premium standards. By controlling the supply chain from seed to sale, the company aims to maintain consistency in its product offerings, which include flower, concentrates, and edibles. This vertically integrated approach allows MariMed to capture value at multiple stages of the cannabis lifecycle while building consumer brand loyalty.

Industry Landscape

The United States cannabis sector continues to navigate a complex regulatory environment as discussions regarding federal rescheduling persist. While various state-level markets mature, operators like MariMed face intense competition from both established multi-state peers and illicit market participants. Growth in the broader industry is currently driven by the transition of more states to adult-use legal frameworks and the strategic expansion of retail footprints. However, the sector remains capital-intensive, with high costs of capital and federal tax regulations, such as Section 280E, impacting the cash flow and net profitability of many publicly traded entities in the cannabis space.

Source verified

SEC filing by MariMed Inc. announcing its third quarter 2026 financial results.

Read the filing ↗

Track MARIMED INC. live

Get the next MARIMED INC. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.